Piotr Czempik

Strona internetowa Kontakt: praktyka

Piotr Czempik Dr hab. Obronił doktorat i od tego czasu jest nauczycielem akademickim.

Piotr Czempik, specjalista anestezjologii i intensywnej terapii, ukończył Śląski Uniwersytet Medyczny w Katowicach, uzyskał tytuł specjalisty i nagrodę Ministra Zdrowia w 2017 r.

I am pleased to share our newly published clinical image article in Polish Archives of Internal Medicine: Thromboelastom...
08/09/2026

I am pleased to share our newly published clinical image article in Polish Archives of Internal Medicine: Thromboelastometry‑guided anticoagulation in severely thrombocytopenic patients with venous thromboembolism: three illustrative cases.

Managing venous thromboembolism (VTE) in patients with severe thrombocytopenia remains a major clinical challenge. Guidelines often recommend dose reduction or temporary interruption of anticoagulation, and platelet transfusion practices vary widely. In this context, rotational thromboelastometry (ROTEM) can provide valuable real‑time insight into clot quality that conventional laboratory tests cannot fully capture.
In our article, we present three illustrative cases of patients with acute VTE and platelet counts below 50 × 10⁹/L, in whom ROTEM helped guide individualized anticoagulation decisions. Despite profound thrombocytopenia, ROTEM consistently demonstrated preserved platelet contribution to clot strength, allowing safe optimization of LMWH dosing and avoidance of unnecessary platelet transfusions.
This work highlights the potential role of viscoelastic testing in refining anticoagulation strategies in complex hematologic and oncologic patients.
I would like to thank the co-authors: Martyna Kurcz, Marta Pietrukaniec, and prof. Michał Holecki.

Thrilled to announce our new publication examining a paradox in anticoagulation therapy.In a profoundly cachectic ICU pa...
09/07/2026

Thrilled to announce our new publication examining a paradox in anticoagulation therapy.
In a profoundly cachectic ICU patient, we observed unexpectedly low anti‑Xa activity despite very high dalteparin doses — a pattern opposite to what conventional pharmacokinetic reasoning would predict.
Cachexia, capillary leak, impaired subcutaneous absorption, and augmented renal clearance combined to produce subtherapeutic anticoagulation.
This case reinforces a critical message: low-molecular-wight heparin dosing in cachectic critically ill patients cannot rely on standard weight‑based regimens — anti‑Xa monitoring is indispensable.

Słowa kluczowe: anti-Xa activitycachexiaintensive care unitlow-molecular-weight heparinpharmacokineticspulmonary embolismsepsis

🚨 New Publication Alert!Proud to share our recent case report and literature review on Chryseobacterium indologenes as a...
29/06/2026

🚨 New Publication Alert!
Proud to share our recent case report and literature review on Chryseobacterium indologenes as a rare but serious cause of ventilator‑associated pneumonia (VAP).
This pathogen is often overlooked — yet as our case shows, it can be the sole aetiological agent in critically ill patients and carries high mortality when not promptly recognized.
💡 Key takeaway: Early identification and targeted therapy matter. In our patient, precise microbiological diagnostics and tailored treatment with trimethoprim + sulfamethoxazole led to clear clinical improvement, despite the organism’s extensive multidrug resistance.
As VAP continues to challenge ICUs worldwide, expanding awareness of emerging pathogens like C. indologenes is essential for improving outcomes.

Please note that since April 10th 2025 there is an NEW obligatory charge (= 600 Euro/3000 PLN) for each manuscript submitted and accepted for publication in journal Medical Studies/Studia Medyczne.

Sepsis remains one of the most urgent challenges in acute care — yet our new national analysis shows that guideline adhe...
19/06/2026

Sepsis remains one of the most urgent challenges in acute care — yet our new national analysis shows that guideline adherence in Poland is still far from where it needs to be.
The Polish arm of the European Sepsis Care Survey (ESCS) shows how sepsis is recognized, managed, and supported at the institutional level in Poland.
🔍 Key findings
• Sepsis‑3 criteria used in only 44% of hospitals
• Screening implemented in 27% of EDs, 21% of wards, 62% of ICUs
• Standardized management present in 38.2% of EDs, 30.8% of wards, 86.7% of ICUs
• Quality Improvement Programs (QIPs) active in just 37% of hospitals
• Regular sepsis training reported by only 6.6%
• Hospitals with QIPs showed dramatically better monitoring of key indicators — including mortality, time‑to‑antibiotics, bundle compliance, and stewardship
💡 Takeaway:
Where structured programs exist, performance improves. Where they don’t, patients are at risk. Strengthening institutional support and embedding systematic QIPs is essential for advancing sepsis care.

Introduction Sepsis is a life-threatening condition and its management should be a hospital priority. The European Sepsis Care Survey (ESCS) investigated the implementation of guideline recommendations and the availability of infrastructure for sepsis care across Europe. Our objective was to provide...

Z okazji Dnia Diagnosty Laboratoryjnego składam wszystkim diagnostom najserdeczniejsze życzenia - zdrowia, satysfakcji z...
27/05/2026

Z okazji Dnia Diagnosty Laboratoryjnego składam wszystkim diagnostom najserdeczniejsze życzenia - zdrowia, satysfakcji z pracy i nieustającej pasji.

Dziękuję za Waszą wiedzę, precyzję i ogromny wkład w ratowanie zdrowia i życia pacjentów ❤️

Data 27 maja nie jest przypadkowa – upamiętnia odczytanie w 1961 r. pierwszej litery kodu genetycznego kodującej aminokwas fenyloalaninę, co zapoczątkowało rozwój współczesnej diagnostyki molekularnej.

I am pleased to share our newly published clinical vignette:“Unusual viscoelastic hemostatic phenotype in a patient with...
26/05/2026

I am pleased to share our newly published clinical vignette:
“Unusual viscoelastic hemostatic phenotype in a patient with coexisting antiphospholipid syndrome and Hageman anomaly: a case report”.
This publication documents something truly unique in the field of hemostasis and perioperative medicine:
➡️ the first-ever description of ROTEM findings in a patient with both triple‑positive antiphospholipid syndrome (APS) and factor XII deficiency - Hageman anomaly (HA), evaluated during late pregnancy, just before cesarean delivery.
The coexistence of APS and HA is already exceptionally rare. Adding the physiological hypercoagulability of the third trimester creates a highly complex immuno‑coagulation environment. Yet, despite this prothrombotic background, the patient demonstrated:
• markedly prolonged INTEM clotting time
• markedly prolonged EXTEM clotting time
• otherwise normal pregnancy‑adjusted clot dynamics
This ROTEM phenotype has never been previously described.
From an educational standpoint, the case raises several important questions for clinicians and researchers:
🔬 How do antiphospholipid antibodies interact with the phospholipid‑based reagents used in ROTEM assays?
Although EXTEM is generally considered resistant to lupus anticoagulant, our findings suggest that very high‑titer antiphospholipid antibodies may still interfere with the tissue factor (TF)–phospholipid micelle, delaying clot initiation.
🔬 How does severe HA modify the initiation phase of coagulation in whole‑blood viscoelastic testing?
HA prolongs aPTT but typically has limited impact on ROTEM. Yet in this case, the combination of APS+HA produced a profound effect.
🔬 How should clinicians interpret prolonged ROTEM clotting times in APS/HA patients, especially in the perioperative or peripartum setting?
Importantly, despite the extreme CT prolongation, the patient had no bleeding tendency and underwent an uneventful cesarean section.
This case underscores a key clinical message:
In patients with combined high-titer triple-positive APS and HA, clot initiation in both INTEM and EXTEM may be markedly prolonged, indicating that ROTEM may not reliably confirm normal hemostasis in this clinical setting. The explanation for EXTEM CT prolongation is hypothetical, and further mechanistic studies are needed to clarify this laboratory phenomenon.


Acta Haematologica Polonica

04/05/2026

🩸 Podczas 6. Forum Intensywnej Terapii jednym z tematów poruszonych przed kamerą „Pulsu Medycyny” było zarządzanie krwią pacjenta hospitalizowanego, czyli Patient Blood Management (PBM). Jak podkreśla dr hab. n. med. i n. o zdr. Piotr Czempik z Zakładu Zarządzania Krwią Pacjenta Katedry Anestezjologii i Intensywnej Terapii Śląski Uniwersytet Medyczny w Katowicach, racjonalne stosowanie składników krwi wymaga dziś nie tylko znajomości progów transfuzji, lecz przede wszystkim właściwej diagnostyki i indywidualizacji decyzji klinicznych.

Link do wideo w komentarzu 👇

Intensywna.pl Instytut Hematologii i Transfuzjologii w Warszawie

I am pleased to share our new publication in Journal of Clinical Medicine (JCM) MDPI :“Hemostasis in Liver Disease Withi...
30/04/2026

I am pleased to share our new publication in Journal of Clinical Medicine (JCM) MDPI :
“Hemostasis in Liver Disease Within Patient Blood Management: A Scoping Review of the Current Literature.”
In this article we mapped current evidence on the complex, rebalanced nature of hemostasis in chronic and acute liver disease and its implications for Patient Blood Management (PBM).
Our review highlights:
• The fragile equilibrium of coagulation in liver disease
• Limitations of conventional coagulation tests
• The growing role of viscoelastic assays and thrombin generation testing
• Evidence‑based PBM strategies that reduce unnecessary transfusion
• Persistent gaps in predicting thrombotic risk and standardizing advanced diagnostics https://www.mdpi.com/2077-0383/15/9/3296


Background/Objectives: The objective of this study was to map and synthesize the current evidence on hemostasis in chronic and acute liver disease within the framework of Patient Blood Management (PBM). Methods: Because research in this field is heterogeneous—spanning mechanistic studies, observat...

How to provide safe and effective antithrombotic prophylaxis in extremely obese patients?Happy to share our latest case ...
28/04/2026

How to provide safe and effective antithrombotic prophylaxis in extremely obese patients?
Happy to share our latest case report addressing this challenging critical care issue.
📘 What the paper covers
Patients >150–200 kg often fail to reach target anti‑Xa levels with standard low-molecular-weight heparin (LMWH) dosing. In our 200‑kg ICU patient, we implemented a fully individualized strategy using:
-weight‑based enoxaparin dosing
-twice‑daily administration
-serial anti‑Xa monitoring
-additional ROTEM analysis for anticoagulation interpretation
-dynamic dose adjustment to maintain intermediate‑intensity antithrombotic prophylaxis
The result: effective VTE prevention with no bleeding events, demonstrating the value of personalized anticoagulation in this high‑risk population.
🔍 Key insight
An initial enoxaparin dose of 0.3 mg/kg SC BID, followed by anti‑Xa–guided adjustment, may offer a rational and safer approach for ICU patients with extreme obesity.

Na naszej stronie internetowej używamy plików cookies. Korzystamy z nich w celu zapewniania odpowiedniego funkcjonowania strony oraz jeżeli wyrazisz na to zgodę, w ustalonych przez nas celach np. analitycznych lub marketingowych. Chcielibyśmy poprosić Cię o zgodę na ich przechowywanie na Two...

Proud to share the latest publication: "Platelet Function and Morphology in Patients with Sepsis and Septic Shock: A Ret...
21/04/2026

Proud to share the latest publication: "Platelet Function and Morphology in Patients with Sepsis and Septic Shock: A Retrospective Pilot Study”.

Sepsis remains one of the most challenging conditions in intensive care medicine. While thrombocytopenia is a well‑known prognostic marker, this study explores a deeper question:
👉 Can platelet function and morphology provide additional insight into sepsis severity?
🔍 Key findings:
• Platelet aggregation was impaired across multiple assays despite normal platelet counts and morphology.
• ROTEM‑derived platelet contribution to clot strength remained within normal limits.
• No association was found between platelet function/morphology and ICU mortality.
• An inverse correlation emerged between ROTEM platelet contribution and SOFA score — suggesting a potential link to sepsis severity.
🧬 Takeaway:
Functional platelet deficits may occur even when structural parameters appear normal. This opens the door to refining how we assess coagulation and inflammation in septic patients.

Background: Sepsis remains a leading cause of mortality in the intensive care unit (ICU). Platelets (PLTs) are central to coagulation, inflammation, and the maintenance of endothelial integrity. Although thrombocytopenia is an established prognostic marker in sepsis, alterations in PLT function and....

Adres

Katowice
40-092

Strona internetowa

Powiadomienia

Bądź na bieżąco: wyślemy Ci e-mail, gdy Piotr Czempik opublikuje nowości i promocje. Twój adres e-mail nie zostanie wykorzystany do żadnego innego celu, a subskrypcję możesz anulować w dowolnym momencie.

Kontakt: Praktyka

Wyślij wiadomość do Piotr Czempik:

Skróty

Udostępnij

Kategoria